What is the main purpose of presenting non-GAAP financial measures in this report?

The company is presenting non-GAAP financial measures to provide investors with a clearer view of its underlying operational performance. These measures exclude the impact of items that are considered to be outside of ordinary operations or that affect period-to-period comparability, such as costs associated with exiting a market, insurance settlements, and acquisition-related R&D charges.

What significant strategic decision is highlighted in this filing?

Becton Dickinson & Co. is exiting the blood glucose monitoring (BGM) market. The financial impact of this decision, including one-time costs, is being specifically adjusted for in the reported financial results.

How do the non-GAAP measures assist investors in understanding the company's performance?

The non-GAAP measures aim to help investors view the underlying operating results without the impact of specific events like foreign currency fluctuations, market exits, or acquisition-related charges. This facilitates easier comparisons to prior periods and a better understanding of the core business performance.

What are the limitations of these non-GAAP measures as stated by BD?

BD states that non-GAAP results should not be considered in isolation and are not a substitute for GAAP results. Items excluded from non-GAAP measures may have a material impact on net income, earnings per share, or cash flows calculated under GAAP. Therefore, management uses these measures in conjunction with GAAP results.

BDX 8-K: Earnings & Results

Summary

Becton, Dickinson and Company (BD) has filed an 8-K report detailing its fourth fiscal quarter and full fiscal year 2006 financial results. The key focus of this filing is the company's presentation of non-GAAP financial measures, which aim to provide a clearer view of underlying operational performance by excluding certain one-time or non-operational items. These adjustments are crucial for investors seeking to understand the core business trends unaffected by specific events. The report highlights that BD is exiting the blood glucose monitoring (BGM) market, and the associated costs are being excluded from several key financial metrics such as revenue, cost of product sold, gross profit, selling and administrative expense, operating income, and earnings per share. Additionally, the company is excluding the impact of insurance settlements and an in-process R&D charge related to the acquisition of GeneOhm Sciences Inc. from certain measures. BD emphasizes that these non-GAAP measures are used internally for performance evaluation and planning, and are provided to investors as a supplemental view of financial results, intended to enhance comparability across periods.

Key Highlights

1BD is reporting financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2006.
2The company is presenting financial results using non-GAAP measures to provide a better view of underlying operational performance.
3BD is exiting the blood glucose monitoring (BGM) market, and the associated one-time costs are being excluded from key financial metrics.
4Adjustments are being made to revenues, cost of product sold, gross profit, selling and administrative expense, and operating income to reflect the BGM market exit.
5The company is also excluding insurance settlements and an in-process R&D charge (from the GeneOhm acquisition) from certain financial metrics, including operating income and earnings per share.
6BD believes these non-GAAP measures aid in comparing financial performance across periods and offer additional insight into financial results.
7The press release announcing these results is furnished as Exhibit 99.1 to this 8-K filing.

BECTON DICKINSON & CO 8-K Report, Financial Results (Nov 2, 2006)

Summary

Key Highlights

Frequently Asked Questions